JP2020502182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502182A5 JP2020502182A5 JP2019532927A JP2019532927A JP2020502182A5 JP 2020502182 A5 JP2020502182 A5 JP 2020502182A5 JP 2019532927 A JP2019532927 A JP 2019532927A JP 2019532927 A JP2019532927 A JP 2019532927A JP 2020502182 A5 JP2020502182 A5 JP 2020502182A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical composition
- etoposide
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 15
- 229960005420 etoposide Drugs 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 229940125904 compound 1 Drugs 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 6
- 229960004316 cisplatin Drugs 0.000 claims 6
- 238000001990 intravenous administration Methods 0.000 claims 5
- 238000001802 infusion Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010025327 Lymphopenia Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 231100001023 lymphopenia Toxicity 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436046P | 2016-12-19 | 2016-12-19 | |
| US62/436,046 | 2016-12-19 | ||
| PCT/EP2017/083272 WO2018114776A1 (en) | 2016-12-19 | 2017-12-18 | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502182A JP2020502182A (ja) | 2020-01-23 |
| JP2020502182A5 true JP2020502182A5 (enExample) | 2021-02-04 |
| JP7113826B2 JP7113826B2 (ja) | 2022-08-05 |
Family
ID=60915499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532927A Active JP7113826B2 (ja) | 2016-12-19 | 2017-12-18 | プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11246929B2 (enExample) |
| EP (1) | EP3554495B1 (enExample) |
| JP (1) | JP7113826B2 (enExample) |
| KR (1) | KR102607967B1 (enExample) |
| AU (1) | AU2017384134B2 (enExample) |
| CA (1) | CA3047449C (enExample) |
| ES (1) | ES3040063T3 (enExample) |
| WO (1) | WO2018114776A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| EP3992189A4 (en) * | 2019-06-27 | 2022-12-07 | Medshine Discovery Inc. | QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA PK INHIBITORS |
| WO2022143671A1 (zh) * | 2020-12-28 | 2022-07-07 | 南京明德新药研发有限公司 | 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| CN1861050A (zh) * | 2006-06-21 | 2006-11-15 | 山东蓝金生物工程有限公司 | 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂 |
| JP5658565B2 (ja) | 2007-09-12 | 2015-01-28 | ジェネンテック， インコーポレイテッド | ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法 |
| AU2009221808A1 (en) | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and EGFR antagonists |
| US9296701B2 (en) * | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| SI3057953T1 (sl) * | 2013-10-17 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk |
-
2017
- 2017-12-18 CA CA3047449A patent/CA3047449C/en active Active
- 2017-12-18 EP EP17823090.0A patent/EP3554495B1/en active Active
- 2017-12-18 US US16/462,309 patent/US11246929B2/en active Active
- 2017-12-18 AU AU2017384134A patent/AU2017384134B2/en active Active
- 2017-12-18 JP JP2019532927A patent/JP7113826B2/ja active Active
- 2017-12-18 KR KR1020197020952A patent/KR102607967B1/ko active Active
- 2017-12-18 ES ES17823090T patent/ES3040063T3/es active Active
- 2017-12-18 WO PCT/EP2017/083272 patent/WO2018114776A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rejhová et al. | Natural compounds and combination therapy in colorectal cancer treatment | |
| JP2020033360A5 (enExample) | ||
| JP2020523356A5 (enExample) | ||
| JP2020509024A5 (enExample) | ||
| EP2301531A3 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| JP2016528162A5 (enExample) | ||
| JP2018184465A5 (enExample) | ||
| JP2018035162A5 (enExample) | ||
| JP2020523359A5 (enExample) | ||
| JP2020502182A5 (enExample) | ||
| JP2009536956A5 (enExample) | ||
| JP2008517991A5 (enExample) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| Marcu | Improving Therapeutic Ratio in Head and Neck Cancer with Adjuvant and Cisplatin‐Based Treatments | |
| JP2017516842A5 (enExample) | ||
| JP2019510807A5 (enExample) | ||
| AR111803A1 (es) | Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2011500650A5 (enExample) | ||
| JP2017514829A5 (enExample) | ||
| ES2896051T3 (es) | Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral | |
| Hollebecque et al. | Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients | |
| Leon-Ferre et al. | Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature | |
| JP2019517474A5 (enExample) |